Related Experiment Videos
Malignant tumors after renal transplantation
Mehmet Haberal1, Hamdi Karakayali, Remzi Emiroğlu
1Başkent University Transplantation Center, Ankara, Turkey. melekk@basknet-ank.edu.tr
Artificial Organs
|August 29, 2002
Summary
Renal transplant recipients face significantly higher cancer risks. Cyclosporine A (CsA) use was linked to increased Kaposi
Area of Science:
- Nephrology
- Oncology
- Immunosuppression
Background:
- Renal transplant recipients exhibit malignancy rates 14-500 times higher than the general population.
- Malignant tumors affect younger patients post-transplant, with incidence increasing annually.
- Previous studies report tumor prevalence in kidney recipients ranging from 4% to 18%.
Purpose of the Study:
- To analyze malignancy development in renal transplant recipients.
- To compare cancer incidence across different immunosuppressive regimens.
- To identify specific immunosuppressants associated with increased malignancy risk.
Main Methods:
- Retrospective analysis of 50 renal transplant recipients who developed malignancy.
- Patients received immunosuppressive therapy including prednisolone (P), azathioprine (AZA), cyclosporine A (CsA), or mycophenolate mofetil (MMF).
- Comparison of malignancy types and incidence rates among treatment groups.
Main Results:
- 52 malignancy cases were recorded in 50 patients (3.7%) treated with P+AZA, P+CsA+AZA, or P+CsA+MMF since 1975.
- Patients receiving Cyclosporine A (CsA) showed a higher incidence of Kaposi's sarcoma.
- No significant statistical differences in other tumor types were observed across treatment groups.
Conclusions:
- Immunosuppressive therapy in renal transplantation is associated with a substantial increase in malignancy risk.
- Cyclosporine A (CsA) may be linked to a higher risk of Kaposi's sarcoma in renal transplant recipients.
- Further research is needed to elucidate the specific oncogenic risks of different immunosuppressive agents.